Search Results for:
-
TAXOL COMPETITION HEATS UP
and Boulder, Colo.-based Hauser Chemical Research announced that they will work together to commercialize Hauser's compound paclitaxel, and to develop new taxane-related drugs for cancer and other diseases. (See BioWorld Today, May 16, 1994, p. 4.) Hauser is developing a cultivar program, growing yew trees of different species in order to develop a gene pool with the most desirable characteristics for future taxol-based drug developmentBioWorld Today | Tuesday, May 17, 1994 -
APPOINTMENTS AND ADVANCEMENTS
Human Genome Sciences Inc., of Rockville, Md., named Michael Antonaccio as vice president of strategic drug developmentBioWorld Today | Tuesday, May 10, 1994 -
ANOTHER BIG PHARMA-BIOTECH DEAL: ONYX, MILES VENTURE WORTH $75M
We have a strong research base in ras and Miles has a chemical library, and drug development and marketing skills...Walsh said this deal shows how valuable good drug development programs are, noting that the large pharmaceutical companies spend over $1 billion a year on research and development each yearBioWorld Today | Wednesday, May 4, 1994 -
EUROPEAN PATENT DISCLOSURES
for therapy, drug developmentBioWorld Today | Monday, May 2, 1994 -
IBAH BEGINS TRADING AFTER MERGER
In September 1993, Affinity established a wholly-owned subsidiary to provide drug development services to pharmaceutical and biotech companiesBioWorld Today | Monday, May 2, 1994 -
ARRIS IDENTIFIES SMALL MOLECULES THAT BIND TO RECEPTORS
We are now using the compounds identified in our growth factor mimetics program to move forward to the challenging research in the structure-based design phase of our drug-development processBioWorld Today | Thursday, April 21, 1994 -
WASHINGTON NEWS BRIEFS PROTOCOL SET FOR AIDS TRIPLE-DRUG COMBINATIONS
Sixteen pharmaceutical companies from the year-old Inter-Company Collaboration on AIDS Drug Development (ICC) have reached a consensus on a protocol to allow rapid evaluation of triple drug combinations for the treatment of AIDS...ICC scientific chair, Juergen Drews of Hoffman-La Roche made the announcement Thursday at the first meeting of the National Task Force on AIDS Drug Development (NTFADD) in Arlington, VaBioWorld Today | Friday, April 15, 1994 -
CORTEX EXTENDS WARRANT PERIODS
The proceeds will be used to advance clinical trials and drug development, said company president Alan SteigrodBioWorld Today | Wednesday, March 23, 1994 -
GENELABS GAINS ACCESS TO CHINA VIA COLLABORATION
and the recently established Shanghai New Drug Development Center signed an agreement last week to collaborate in the development and manufacture of new drugs, including a lupus medication now about to enter Phase III clinical trials in the U.S. Genelabs (NASDAQ:GNLB) of Redwood City, Calif., will establish joint ventures with two pharmaceutical companies in Shanghai (the center of the Chinese biotechnology and pharmaceuticals industryBioWorld Today | Tuesday, March 22, 1994 -
LA JOLLA FILES IPO FOR 2.8M SHARES
Stemler described completion of the plant as a major step toward the company's goal of human clinical trials in 1994, following its successful drug development/animal testing programBioWorld Today | Friday, March 18, 1994 -
AMI, ASTRA/MERCK TEAM FOR ULCER DRUG
Astra/Merck's president, Wayne Yetter, noted that the company, which is currently owned by Merck & Co., "anticipates becoming, in the near future, a 50-50 joint-venture company focusing on taking the pharmaceutical discoveries of others through the drug development process to the marketplaceBioWorld Today | Friday, March 4, 1994 -
IS BIO OVERSIMPLIFYING BIOTECH FINANCING 'CRISIS'?
Viagene did cut back to three clinical trials from a planned five for a new HIV drug in development, but the company's president, Robert Abbott, conceded that overall market setbacks such as Synergen's and Centocor's disasters could be cited as significant reasons for Viagene's travails in going public and raising fundsBioWorld Today | Thursday, March 3, 1994 -
AFFYMAX TO COLLABORATE WITH WYETH-AYERST
Affymax's focus on drug discovery lends itself to this strategy, she explained, because the company can look to bigger partners for input in the expensive process of drug development and commercializationBioWorld Today | Tuesday, March 1, 1994 -
REPORT ENCOURAGES INCLUDING PREGNANT WOMEN
The idea that women are left out of drug development trials is just wrong," said Robert Temple, director of the FDA's Office of Drug Evaluation IBioWorld Today | Friday, February 25, 1994 -
ISIS DISCOVERS ANTI-HIV COMPOUND
Isis has been focusing on identifying improved oligonucleotide chemistries for antisense drug developmentBioWorld Today | Thursday, February 24, 1994 -
INTERNEURON LICENSES COMPOUND FROM RHONE
is adding an anti-anxiety compound to its drug-development portfolio through a licensing agreement with Rhone-Poulenc Rorer...Rhone-Poulenc decided to license out the compound when it shifted its drug-development prioritiesBioWorld Today | Wednesday, February 23, 1994 -
ONCOGENE INKS PACT TO DEVELOP LEAD COMPOUNDS
These are the first lead compounds identified in Oncogene's proprietary drug development programBioWorld Today | Wednesday, February 9, 1994 -
SMALL BUDGET INCREASE PROPOSED FOR NIH
The new budget would also include $51 million for tuberculosis, a tenfold increase over the fiscal 1991 budget, some of which would contribute to physical mapping, and DNA sequencing of the bacillus, as well as more drug-development effortsBioWorld Today | Tuesday, February 8, 1994 -
PANEL NAMED TO SPEED AIDS RESEARCH
That group, Braverman said, is interested in later phases of drug development, but "the effort should be screening at the preclinical level for pharmacokinetics and pharmacodynamics of compounds, and issues such as differences in metabolism and toxicities based on race and gender...Moreover, to be effective, the committee must be able to influence other committees, such as the AIDS Clinical Drug Development Committee, which grades new drugs after clinical trials but prior to FDA approval, and FDA'sBioWorld Today | Tuesday, February 8, 1994 -
MYCO GETS NIH GRANT FOR FUNGAL RESEARCH
Drug development in the company's three therapeutic areas is based on the genetic engineering of fungi, an approach Berkowitz said is "used as a very broad platform to solve problems and do drug discoveryBioWorld Today | Monday, February 7, 1994
Category
Current Filters
- xdrug development
Related Keywords
Categories
- x BioWorld Today (2546)
- x BioWorld International (630)
- x BioWorld Insight (361)
- x Bio Perspectives (145)
- x BioWorld Genomics Review (91)
- x State of the Industry Report (58)
- x Top 25 Drug Report (38)
- x BioWorld Snapshots (29)
- x RNAi Report (11)
- x Biotech Innovations (10)
- x Market-Leading Biotech Drugs (4)
- x Executive Compensation Report (3)
- x Recorded (2)
- x Featured (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.